A/Prof Dipti Talaulikar

Clinical Haematologist
Become a Patient

A/Prof Dipti Talaulikar is dedicated to improving patient wellbeing and tailoring personalised treatment plans for those in her care. She combines an active interest in clinical research with an extensive understanding of cancer care to achieve the best possible outcome for her patients.


A/Prof Dipti Talaulikar is an experienced clinical haematologist at Icon Cancer Centre Canberra. In 2003, she established her haematology career in Canberra as an advanced trainee haematology registrar at Canberra Hospital whilst completing post-graduate studies at the Australian National University (ANU). A/Prof Talaulikar has completed a graduate certificate in higher education and PhD investigating occult bone marrow involvement in Diffuse Large B-cell lymphoma. She is a senior fellow of the ANU Higher Education Academy (HEA).

A/Prof Talaulikar maintains a strong interest in medical leadership, research and clinical trials in both her private practice and role as senior staff specialist at Canberra Hospital. She has been principal investigator and co-investigator of several lymphoma, leukaemia and myeloma trials. She is an Associate Professor (Level D) of the College of Medicine, Biology and Environment at ANU and is actively involved in the academic supervision and teaching of emerging medical professionals. She is a member of several leading cancer trial and research groups including the Australasian Leukaemia & Lymphoma Group (ALLG), Australian Lymphoma Alliance, American Society of Haematology (ASH) and Haematology Society of Australia and New Zealand (HSANZ). She is also a member of the Medical & Scientific Advisory Group (MSAG) of Myeloma Australia & a steering committee member of the Lymphoma and Related Diseases Registry (LaRDR).

A/Prof Talaulikar has published several clinical research articles and practice guidelines in leading publications, including the Journal of Internal Medicine and British Journal of Haematology. She is also a regular invited speaker at national and international haematology conferences. A/Prof Talaulikar is a fellow of the Royal Australasian College of Physicians (FRACP) and Royal College of Pathologists of Australasia (FRCPA). Her clinical experience covers a broad range of malignant blood disorders with a special interest in leukaemia, myeloma, lymphoma and myeloproliferative neoplasms.

Affiliations & Memberships

  • Australasian Leukaemia & Lymphoma Group (ALLG)
  • American Society of Haematology (ASH)
  • European Haematology Association (EHA)
  • Haematology Society of Australia and New Zealand (HSANZ)
  • International Society of Laboratory Haematology (ISLH)
  • Lymphoma and Related Diseases Registry (LaRDR)
  • Myeloma Scientific & Advisory Group (MSAG)

Special Interests

A/Prof Dipti Talaulikar accepts referrals for all malignant blood disorders, with a special clinical interest in:
  • Leukaemia
  • Lymphoma
  • Multiple myeloma
  • Myeloproliferative neoplasms

Icon Locations

Canberra View centre

Visiting Locations

  • Canberra Hospital
  • Canberra Regional Cancer Centre


  • LAG3: A Novel Immune Checkpoint Expressed by Multiple Lymphocyte Subsets in Diffuse Large B-cell Lymphoma. C. Keane, S.C. Law, C. Gould, S. Birch, M.B. Sabdia L.¬† Merida de Long, G. Thillaiyampalam, E. Abro, J.W. Tobin, X. Tan, Z.Y. Xu-Monette, K.H. Young, G. Gifford, S. Gabreilli, W.S. Stevenson, A. Gill, D. Talaulikar, S. Jain, A. Hernandez, S.J. Halliday, R. Bird, D. Cross, M. Hertzberg & M.K. Gandhi. Blood Advances, 2020 Apr 14; 4(7):1367-1377.

  • Diagnosis and Follow Up in Waldenstr√∂m Macroglobulinaemia: Recommendations from the Medical and Scientific Advisory Group, Myeloma Australia, the Pathology Sub-committee of the Lymphoma and Related Diseases Registry and the Australasian Association of Clinical Biochemists Monoclonal Gammopathy Working Group. M. Gohar Maqbool, C.S. Tam, I.M. Morison, D. Simpson, P. Mollee, H. Schneider, H.Chan, S. Juneja, Y. Harvey, L. Nath, P. Hissaria, H.M. Prince, H.Wordsworth, S. Opat & D. Talaulikar. Pathology, 2020 Feb; 52(2):167-178.

  • Outcomes of stage I/II follicular lymphoma in the PET era: an international study from the Australian Lymphoma Alliance. J.W.D. Tobin, G. Rule, K. Colvin, L. Calvente, D. Hodgson, S. Bell, C. Dunduru, J. Gallo, E.S. Tsang, X. Tan, J. Wong, J. Pearce, R. Campbell, S. Tneh, S. Shorten, M. Ng, T. Cochrane, C.S. Tam, E. Abro, E. Hawkes, G. Hodges, R. Kansara, D. Talaulikar, M. Gilbertson, A.M. Johnston, K.J. Savage, D. Villa, K. Morris, S. Ratnasingam, W. Janowski, R. Kridel, C.Y. Cheah, M. MacManus, N. Matigian, P. Mollee, M.K. Gandhi & G. Hapgood. Blood Advances, 2019 Oct 8; 3(19):2804-2811.

  • Outcomes of synchronous systemic and central nervous system involvement of diffuse large B-cell lymphoma are dictated by the CNS disease: A collaborative study of the Australasian Lymphoma Alliance. J. Wight, M. Yue, C. Keane, A. Johnston, K. Linton, C. Chin, S.H. Wai, D. Talaulikar, R. Gasiorowski, C.Y. Cheah, G.P. Gregory, M. Dickinson, A. Minson, C. Coombes, M. Ku, S. Lam & E.A. British Journal of Haematology, 2019 Jun 24; 187(2):174-184.